Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                
Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • NEWS

First US drug approved for a liver disease surging around the world

A therapy called resmetirom improves hallmarks of an obesity-linked condition that can lead to liver failure.
  1. Heidi Ledford
    View author publications

    You can also search for this author in PubMed  Google Scholar

For the first time, the US Food and Drug Administration has approved a drug to treat an obesity-linked liver disease that is on the rise around the globe and is becoming a leading driver of liver failure and transplants.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

doi: https://doi.org/10.1038/d41586-024-00747-9

References

  1. Harrison, S. A. et al. N. Engl. J. Med. 390, 497–509 (2024).

    Article  PubMed  Google Scholar 

  2. Newsome, P. N. et al. N. Engl. J. Med. 384, 1113–1124 (2021).

    Article  PubMed  Google Scholar 

Download references

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links